PubRank

James S Tomlinson

Author PubWeight™ 47.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol 2008 2.20
2 Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008 1.90
3 Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2008 1.82
4 Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol 2010 1.82
5 Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 2007 1.63
6 Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg 2011 1.59
7 Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007 1.44
8 Are 12 nodes needed to accurately stage T1 and T2 colon cancers? Dig Dis Sci 2008 1.44
9 Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002 1.42
10 Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 2007 1.41
11 Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 2005 1.37
12 Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol 2008 1.32
13 Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 2002 1.18
14 Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg 2011 1.12
15 Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 2010 1.09
16 Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 2002 1.08
17 Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res 2011 1.06
18 Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014 1.06
19 Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia 2009 1.05
20 Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg 2008 1.05
21 Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms. Gastroenterology 2009 1.04
22 Patient satisfaction: an increasingly important measure of quality. Ann Surg Oncol 2006 1.02
23 Impact of adjuvant radiation on survival: a note of caution when using cancer registry data to evaluate adjuvant treatments. Ann Surg Oncol 2007 1.00
24 Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer 2010 1.00
25 Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res 2011 0.94
26 Quality of pancreatic cancer care at Veterans Administration compared with non-Veterans Administration hospitals. Am J Surg 2007 0.93
27 Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer. J Gastrointest Surg 2014 0.91
28 Trends, patterns, and outcomes in the management of malignant colonic polyps in the general population of the United States. Cancer 2010 0.91
29 An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol 2012 0.90
30 Utilization of parenteral nutrition following pancreaticoduodenectomy: is routine jejunostomy tube placement warranted? Dig Dis Sci 2008 0.89
31 CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imaging 2011 0.89
32 Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol 2013 0.88
33 Cystic neoplasms of the pancreas: results of 114 cases. Pancreas 2010 0.87
34 Unexpected readmissions after major cancer surgery: an evaluation of readmissions as a quality-of-care indicator. Surg Oncol Clin N Am 2012 0.86
35 An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. J Surg Res 2013 0.85
36 Comorbidities play a larger role in predicting health-related quality of life compared to having an ostomy. Am J Surg 2007 0.83
37 Quality of care in surgical oncology. Cancer Control 2009 0.81
38 Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. J Gastrointest Surg 2013 0.81
39 A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. Mol Imaging Biol 2014 0.80
40 Perioperative antibiotics for surgical site infection in pancreaticoduodenectomy: does the SCIP-approved regimen provide adequate coverage? Surgery 2013 0.79
41 Metabolic exploitation of the sialic acid biosynthetic pathway to generate site-specifically labeled antibodies. Glycobiology 2013 0.77
42 Molecular Imaging Probe Development using Microfluidics. Curr Org Synth 2011 0.76
43 Mesenteric rheumatoid nodules masquerading as an intra-abdominal malignancy: a case report and review of the literature. World J Surg Oncol 2009 0.75
44 Circulating Tumor Cells in Gastrointestinal Cancer: Current Practices and Future Directions. Cancer Treat Res 1 0.75